143 related articles for article (PubMed ID: 32803488)
1. High expression of microRNA20b is associated with malignant clinicopathological features and poor prognosis in breast phyllodes tumor.
Lei T; Yin L; Zhang H; Wei B; Chen H; Pu T; Yang L; Ye F; Zhang Z; Bu H
Int J Clin Oncol; 2020 Dec; 25(12):2025-2034. PubMed ID: 32803488
[TBL] [Abstract][Full Text] [Related]
2. Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis.
Kwon JE; Jung WH; Koo JS
Tumour Biol; 2012 Jun; 33(3):787-98. PubMed ID: 22203494
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression in the epithelial components of mammary phyllodes tumors.
Tsang JY; Mendoza P; Putti TC; Karim RZ; Scolyer RA; Lee CS; Pang AL; Tse GM
Hum Pathol; 2012 Dec; 43(12):2117-23. PubMed ID: 22820000
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers in breast phyllodes tumor.
Kim SI; Koo JS
Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
[TBL] [Abstract][Full Text] [Related]
5. Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin.
Taira N; Takabatake D; Aogi K; Ohsumi S; Takashima S; Nishimura R; Teramoto N
Jpn J Clin Oncol; 2007 Oct; 37(10):730-6. PubMed ID: 17932112
[TBL] [Abstract][Full Text] [Related]
6. Expression of Yes-associated protein (YAP) in breast phyllodes tumor.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2014; 7(9):5997-6005. PubMed ID: 25337244
[TBL] [Abstract][Full Text] [Related]
7. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors.
Kim GE; Kim JH; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):298-303. PubMed ID: 22505012
[TBL] [Abstract][Full Text] [Related]
8. Analysis of phyllodes tumor recurrence according to the histologic grade.
Kim S; Kim JY; Kim DH; Jung WH; Koo JS
Breast Cancer Res Treat; 2013 Oct; 141(3):353-63. PubMed ID: 24062207
[TBL] [Abstract][Full Text] [Related]
9. Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast.
Feng X; Zhao L; Shen H; Liu X; Yang Y; Lv S; Niu Y
Oncotarget; 2017 May; 8(20):33365-33374. PubMed ID: 28380418
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour.
Tsang JY; Ni YB; Ng EK; Shin VY; Mak KF; Go EM; Tawasil J; Chan SK; Ko CW; Kwong A; Tse GM
Histopathology; 2015 Sep; 67(3):294-305. PubMed ID: 25585495
[TBL] [Abstract][Full Text] [Related]
11. Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast.
Koh VCY; Thike AA; Nasir NDM; Yip GWC; Bay BH; Tan PH
Virchows Arch; 2018 Apr; 472(4):615-621. PubMed ID: 29127495
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic analysis of benign, borderline and malignant phyllodes tumors of the breast].
Wang H; Wang X; Wang C
Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):923-7. PubMed ID: 26887622
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
14. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
15. Malignant phyllodes tumors of the breast: the malignancy grading and associations with prognosis.
Liu J; Li F; Liu X; Lang R; Liang R; Lu H
Breast Cancer Res Treat; 2023 Jun; 199(3):435-444. PubMed ID: 37071267
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
[TBL] [Abstract][Full Text] [Related]
17. The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan.
Lin CC; Chang HW; Lin CY; Chiu CF; Yeh SP
Int J Clin Oncol; 2013 Aug; 18(4):614-20. PubMed ID: 22773245
[TBL] [Abstract][Full Text] [Related]
18. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast.
Tsang JYS; Hui YK; Lee MA; Lacambra M; Ni YB; Cheung SY; Wu C; Kwong A; Tse GMK
Sci Rep; 2018 Mar; 8(1):3881. PubMed ID: 29497099
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.
Spanheimer PM; Murray MP; Zabor EC; Stempel M; Morrow M; Van Zee KJ; Barrio AV
Ann Surg Oncol; 2019 Jul; 26(7):2136-2143. PubMed ID: 30783853
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome.
Onkendi EO; Jimenez RE; Spears GM; Harmsen WS; Ballman KV; Hieken TJ
Ann Surg Oncol; 2014 Oct; 21(10):3304-9. PubMed ID: 25034817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
